XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | 1.61 | 1.94 | +20.50% | $814.5M | ✅ Beat | +5.51% | +15.36% | — |
| 2026-02-11 | Q4 2025 | 2.09 | 1.88 | -10.05% | $805.5M | ❌ Miss | -3.59% | -6.59% | -5.57% |
| 2025-10-28 |
| Q3 2025 |
| 1.87 |
| 2.17 |
| +16.04% |
| $794.9M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-30 | Q2 2025 | 1.27 | 1.65 | +29.92% | $687.5M | ✅ Beat | — | — | — |
| 2025-05-05 | Q1 2025 | 1.09 | 0.70 | -35.78% | $572.6M | ❌ Miss | — | — | — |
| 2025-02-06 | Q4 2024 | 1.71 | 1.69 | -1.17% | $627.7M | ❌ Miss | — | — | — |
| 2024-10-30 | Q3 2024 | 1.51 | 1.81 | +19.87% | $622.1M | ✅ Beat | — | — | — |
| 2024-08-01 | Q2 2024 | 1.03 | 1.63 | +58.25% | $590.2M | ✅ Beat | — | — | — |
Showing last 8 quarters.